{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:39:30Z","timestamp":1791005970209,"version":"4.1.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The term spondyloarthritis pertains to both axial and peripheral arthritis including ankylosing spondylitis (AS) and psoriatic arthritis (PsA), which is strongly linked to psoriasis and also the arthritis associated with inflammatory bowel disease. The argument supporting the role for IL-23 across the spectrum of SpA comes from 4 sources. First, genome wide associated studies (GWAS) have shown that all the aforementioned disorders exhibit IL-23R pathway SNPs, whereas HLA-B27 is not linked to all of these diseases-hence the IL-23 pathway represents the common genetic denominator. Secondly, experimental animal models have demonstrated a pivotal role for the IL-23\/IL-17 axis in SpA related arthropathy that initially manifests as enthesitis, but also synovitis and axial inflammation and also associated aortic root and cutaneous inflammation. Thirdly, the emergent immunology of the human enthesis also supports the presence of IL-23 producing myeloid cells, not just at the enthesis but in other SpA associated sites including skin and gut. Finally, drugs that target the IL-23 pathway show excellent efficacy for skin disease, efficacy for IBD and also in peripheral arthropathy associated with SpA. The apparent failure of IL-23 blockade in the AS which is effectively a spinal polyenthesitis but evidence for efficacy of IL-23 inhibition for peripheral enthesitis in PsA and preliminary suggestions for benefit in axial PsA, raises many questions. Key amongst these is whether spinal inflammation may exhibit entheseal IL-17A production independent of IL-23 but peripheral enthesitis is largely dependent on IL-23 driven IL-17 production. Furthermore, IL-23 blocking strategies in animal models may prevent experimental SpA evolution but not prevent established disease, perhaps pointing towards a role for IL-23 in innate immune disease initiation whereas persistent disease is dependent on memory T-cell responses that drive IL-17A production independently of IL-23, but this needs further study. Furthermore, IL-12\/23 posology in inflammatory bowel disease is substantially higher than that used in AS trials which merits consideration. Therefore, the IL-23 pathway is centrally involved in the SpA concept but the nuances and intricacies in axial inflammation that suggest non-response to IL-23 antagonism await formal definition. The absence of comparative immunology between the different skeletal sites renders explanations purely hypothetical at this juncture.<\/jats:p>","DOI":"10.3389\/fimmu.2021.614255","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T06:01:07Z","timestamp":1616133667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Dennis","family":"McGonagle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla","family":"Watad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassem","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Bridgewood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197409000-00002","article-title":"Associations between ankylosing spondylitis, psoriatic arthritis, Reiter\u2019s disease, the intestinal arthropathies, and Behcet\u2019s syndrome","volume":"53","author":"Moll","year":"1974","journal-title":"Med (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.04.002","article-title":"Nature versus nurture in the spectrum of rheumatic diseases: Classification of spondyloarthritis as autoimmune or autoinflammatory","volume":"17","author":"Generali","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.autrev.2017.11.006","article-title":"Is undifferentiated spondyloarthritis a discrete entity","volume":"17","author":"Deodhar","year":"2018","journal-title":"A Debate Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02668","article-title":"The early phases of ankylosing spondylitis: emerging insights from clinical and basic science","volume":"9","author":"Watad","year":"2018","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000529","article-title":"Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics","volume":"30","author":"Bridgewood","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)91360-3","article-title":"Ankylosing spondylitis and HL-A 27","volume":"301","author":"Brewerton","year":"1973","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1186\/ar571","article-title":"HLA-B27: natural function and pathogenic role in spondyloarthritis","volume":"4","author":"McMichael","year":"2002","journal-title":"Arthritis Res Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.02.002","article-title":"An update on biomarkers in axial spondyloarthritis","volume":"15","author":"Prajzlerova","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2015.147","article-title":"\u2018MHC-I-opathy\u2019\u2014unified concept for spondyloarthritis and Beh\u00e7et disease","volume":"11","author":"McGonagle","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ajhg.2009.01.026","article-title":"Diverse genome-wide association studies associate the IL12\/IL23 pathway with Crohn Disease","volume":"84","author":"Wang","year":"2009","journal-title":"Am J Hum Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veale","year":"2019","journal-title":"Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B14","volume-title":"OP0054 Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the P19-Subunit of Il-23, on Endpoints Related to Axial Involvement in Patients With Active Psa With Imaging-Confirmed Sacroiliitis: Week-24 Results From Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies.","author":"Helliwell","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.40759","article-title":"Ustekinumab fails to show efficacy in a phase III axial spondyloarthritis program: the importance of negative results","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-272153","article-title":"Low-strength T-cell activation promotes Th17 responses","volume":"116","author":"Purvis","year":"2010","journal-title":"Blood J Am Soc Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02933","article-title":"Genetics and functional genomics of spondyloarthritis","volume":"9","author":"Costantino","year":"2018","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of ankylosing spondylitis\u2014insights into pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2011.238477","article-title":"Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease","volume":"60","author":"Kim","year":"2011","journal-title":"Gut"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.08.013","article-title":"The immunogenetics of Beh\u00e7et\u2019s disease: A comprehensive review","volume":"64","author":"Takeuchi","year":"2015","journal-title":"J Autoimmun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","year":"2007","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017854108","article-title":"Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses","volume":"108","author":"Sarin","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Di Meglio","year":"2011","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/1529-0131(199804)41:4<694::AID-ART17>3.0.CO;2-#","article-title":"Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy","volume":"41","author":"McGonagle","year":"1998","journal-title":"Arthritis Rheumatism: Off J Am Coll Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)12004-9","article-title":"Classification of inflammatory arthritis by enthesitis","volume":"352","author":"McGonagle","year":"1998","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11926-018-0751-3","article-title":"Enthesitis: much more than focal insertion point inflammation","volume":"20","author":"Watad","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203643","article-title":"Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells","volume":"73","author":"Jacques","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209454","article-title":"A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis","volume":"76","author":"De Wilde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+ CD4\u2013 CD8\u2013 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.39732","article-title":"Interleukin-23\u2013dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00761","article-title":"Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications","volume":"8","author":"Lawand","year":"2017","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003986","article-title":"IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass","volume":"187","author":"Adamopoulos","year":"2011","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21248","article-title":"IL-23\/IL-17 axis in IBD","volume":"16","author":"Sarra","year":"2010","journal-title":"Inflam Bowel Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.38638","article-title":"Interleukin-23 mediates the intestinal response to microbial \u03b2-1, 3-glucan and the development of spondyloarthritis pathology in SKG mice","volume":"66","author":"Benham","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1818812116","article-title":"Mutual interplay between IL-17\u2013producing \u03b3\u03b4T cells and microbiota orchestrates oral mucosal homeostasis","volume":"116","author":"Wilharm","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1053\/j.gastro.2018.06.034","article-title":"Diet modifies colonic microbiota and CD4+ T-cell repertoire to induce flares of colitis in mice with myeloid-cell expression of interleukin 23","volume":"155","author":"Chen","year":"2018","journal-title":"Gastroenterology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.imlet.2018.01.014","article-title":"The role of gut microbiota and IL-23\/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates","volume":"196","author":"Babaie","year":"2018","journal-title":"Immunol Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2008.09.009","article-title":"Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine","volume":"4","author":"Ivanov","year":"2008","journal-title":"Cell Host Microbe"},{"key":"B45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.berh.2018.07.004","article-title":"The SKG model of spondyloarthritis","volume":"31","author":"Rahman","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1561281","article-title":"The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond","volume":"15","author":"Dubash","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X13501021","article-title":"Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential","volume":"5","author":"Gottlieb","year":"2013","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.515804","article-title":"Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial","volume":"26","author":"Kavanaugh","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30460-8","article-title":"The psychological impact of quarantine and how to reduce it: rapid review of the evidence","volume":"395","author":"Brooks","year":"2020","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/art.40150","article-title":"Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis","volume":"69","author":"Cuthbert","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/art.10125","article-title":"The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy","volume":"46","author":"McGonagle","year":"2002","journal-title":"Arthritis Rheumatism"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/cells10020341","article-title":"IL-17A and TNF Modulate Normal Human Spinal Entheseal Bone and Soft Tissue Mesenchymal Stem Cell Osteogenesis, Adipogenesis, and Stromal Function","volume":"10","author":"Russell","year":"2021","journal-title":"Cells"},{"key":"B61","first-page":"1","article-title":"Cytokine \u201cfine tuning\u201d of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies","volume-title":"Semin Immunopathol Springer","author":"Russell","year":"2021"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213654","article-title":"Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation","volume-title":"Ann Rheum Dis","author":"Siebert","year":"2019"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front Pharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Digest Dis Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA","volume":"61","author":"O\u2019Toole","year":"2016","journal-title":"Digest Dis Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J Dermatol Treat"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.2140","article-title":"OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/art.22758","article-title":"The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheumatism"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120216","article-title":"\u03b3\u03b4 T cells: first line of defense and beyond","volume":"32","author":"Chien","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Newton, Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0191-y","article-title":"Mucosal-associated invariant T cells and disease","volume":"19","author":"Toubal","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.1914","volume-title":"OP0302 Mucosal-Associated Invariant T (MAIT)-Cell-Derived IL-17A and IL-17F Production IS IL-23-Independent and Biased TowardS IL-17F.","author":"Cole","year":"2019"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219047","article-title":"Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression","volume":"79","author":"Watad","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00920","article-title":"Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27\/Hu\u03b22m Transgenic Rats","volume":"8","author":"van Tok","year":"2017","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/art.24599","article-title":"Spondylarthritis in HLA-B27\/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8","volume":"60","author":"Taurog","year":"2009","journal-title":"Arthritis Rheumatism"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/art.40778","article-title":"Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for\u00a0Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two\u2013Week, Prospective, Open-Label Feasibility Study","volume":"71","author":"Savage","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-019-01235-x","article-title":"The IL-23p19\/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man","volume":"68","author":"Bridgewood","year":"2019","journal-title":"Inflamm Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.03.026","article-title":"Revisiting the combinatorial potential of cytokine subunits in the IL-12 family","volume":"165","author":"Detry","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.038","article-title":"Ustekinumab for Crohn\u2019s Disease","volume":"152","author":"Khanna","year":"2017","journal-title":"Gastroenterology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/art.38050","article-title":"Magnetic resonance imaging assessment of axial psoriatic arthritis: extent of disease relates to HLA-B27","volume":"65","author":"Castillo-Gallego","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"B90","doi-asserted-by":"publisher","first-page":"iv67","DOI":"10.1093\/rheumatology\/keaa408","article-title":"Intestinal and enthesis innate immunity in early axial spondyloarthropathy","volume":"59","author":"Sharif","year":"2020","journal-title":"Rheumatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.614255\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T06:01:14Z","timestamp":1616133674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.614255\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":90,"alternative-id":["10.3389\/fimmu.2021.614255"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.614255","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"article-number":"614255"}}